PUBLIC COMPANY
save$BOLDBoundless Bio, Inc.
$BOLDSan Diego, CA, USupdated 20d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
- phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
- phase1Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
🐶 Hiring Signal
News
- Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the massesThe CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.biopharma_dive · 10d ago
- Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuringTwo and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”fiercebiotech · 15d ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 16d ago
- How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorPoised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.biospace · 1mo ago
- STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expectA new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.stat · 1mo ago
- Building a workforce engine for biomanufacturingOhio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.fiercebiotech · 1mo ago
- Vertex's Crinetics deal points to big ambitions for cystic fibrosis leaderVertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech suc…endpoints · 1mo ago
- STAT+: Four major biotech updates to catch up onAnthropic CEO talks drug discovery, Medicare proposes steep 340B drug payment cuts, and more biotech newsstat · 1mo ago
- Opinion: Why the space in ‘health care’ mattersWhen STAT polled our readers on ‘health care’ vs. ‘healthcare,’ about 60% of our readers voted for one word.stat · 2mo ago
- Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73"There are some physicians that work to 100”: Dawn Zuidgeest-Craft on becoming a medical doctor in her 70s.stat · 2mo ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that